(MENAFN- Straits Research)
Contrast-Enhanced Ultrasound Market Size & Growth Analysis
The global contrast enhanced ultrasound market size was valued at USD 2.19 billion in 2025 and is projected to grow from USD 2.30 billion in 2026 to USD 3.44 billion by 2034, registering a CAGR of 5.14% during the forecast period from 2026 to 2034. North America dominated the contrast enhanced ultrasound market with a market share of 39.5% in 2025.
The introduction of ultrasonic contrast medium to regular medical sonography is called contrast-enhanced ultrasonography (CEUS). Ultrasound contrast agents rely on how sound waves are reflected from material interfaces. This could be the surface of an air bubble or something more complicated. Gas-filled microbubbles are delivered intravenously to the systemic circulation in a commercially available contrast medium.
The echogenicity of microbubbles is very high (the ability of an object to reflect ultrasound waves). The echogenicity of the gas in the microbubbles and the soft tissue surrounding the body are vastly different. Due to the significant echogenicity difference, ultrasonic imaging with microbubble contrast agents intensifies the ultrasound backscatter (reflection) of the ultrasound waves, resulting in a sonogram with higher contrast. Contrast-enhanced ultrasonography can assess blood perfusion in organs and estimate the blood flow rate in the heart and other organs.
Contrast Enhanced Ultrasound Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 2.19 Billion
2026 Market Size: USD 2.30 Billion
2034 Projected Market Size: USD 3.44 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 5.14%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 39.5%
Fastest-Growing Region: Europe
Europe CAGR (2026–2034): 8.12%
Segment Insights
By Product
Leading Segment: Equipment
Market Share in 2025: 61.8%
By Type
Fastest-Growing Segment: Targeted
CAGR: 8.31% (2026–2034)
By End-Use
Leading Segment: Hospitals
Market Share in 2025: 56.7%
Download a Free Sample To learn more about this report,
Contrast Enhanced Ultrasound Market Trends
Expansion of CEUS into Targeted Imaging and Wider Clinical Applications
Contrast-enhanced ultrasound is moving beyond conventional cardiac and liver imaging into pediatrics, inflammatory bowel disease, oncology, infertility assessment, and image-guided procedures. Microbubble agents allow clinicians to observe blood flow and tissue perfusion in real time without ionizing radiation. Demand is also rising for targeted agents that bind to biological markers associated with inflammation or tumor-related blood vessel growth. Meanwhile, automated contrast delivery, advanced transducers, low-mechanical-index imaging, and artificial intelligence are improving image consistency. These developments are making CEUS more useful for lesion characterization, treatment monitoring, and bedside examinations, supporting its adoption across hospitals, specialty clinics, and diagnostic centers.
In Feb 2025 , the U.S. FDA granted Fast Track designation to Bracco's targeted microbubble agent BR55 for detecting active bowel inflammation in patients with Crohn's disease.
Contrast Enhanced Ultrasound Market Dynamics
Market Drivers
Growing Need for Safe, Real-Time Diagnostic Imaging
The increasing burden of cardiovascular disease, liver disorders, cancer, and inflammatory bowel disease is driving demand for accurate diagnostic imaging. CEUS improves visualization of organ perfusion, blood vessels, cardiac chambers, and focal lesions while avoiding ionizing radiation. Its microbubble agents remain mainly within the bloodstream, making the technique useful when CT or MRI contrast agents are unsuitable for certain patients. CEUS can also be performed at the bedside and repeated during follow-up examinations. Wider regulatory indications, improving hospital ultrasound infrastructure, and growing awareness among radiologists and cardiologists are increasing procedure volumes. Pediatric applications provide an additional growth avenue because reducing radiation exposure is particularly important in children.
In May 2025, The U.S. FDA approved GE HealthCare's Optison for pediatric patients with suboptimal echocardiograms, expanding access to clearer cardiac imaging.
Market Restraints
Limited Reimbursement and Uneven Regulatory Coverage
Adoption of contrast-enhanced ultrasound remains restricted by differences in reimbursement, approved indications, and hospital purchasing policies. Although CEUS is widely used for certain liver and cardiac examinations, regulatory coverage for other organs and diseases varies among countries. Some healthcare providers may continue choosing CT or MRI because their reimbursement systems, referral pathways, and reporting procedures are already established. CEUS also requires compatible ultrasound equipment, contrast-specific software, intravenous administration capabilities, and trained staff. Smaller clinics may find these additional investments difficult to justify when examination volumes are low. Limited awareness among referring physicians can further reduce demand, particularly in markets where CEUS is not included in routine clinical protocols.
In Nov 2025 CMS assigned improved payment for certain CEUS procedures in the U.S., highlighting that inadequate reimbursement had remained an important adoption barrier.
Market Opportunities
New Indications and Targeted Microbubbles Create Growth Potential
The strongest opportunities are emerging from new clinical indications, targeted contrast agents, and broader adoption in women's health and gastrointestinal imaging. Targeted microbubbles can attach to disease-related molecular markers, potentially enabling clinicians to identify active inflammation or abnormal tumor blood vessels. CEUS may also support therapy monitoring by showing changes in tissue perfusion immediately after treatment. Expanding its use in fertility assessment, pediatrics, kidney imaging, and interventional procedures can open new revenue streams for agent manufacturers and ultrasound-system providers. Emerging healthcare markets offer further potential because ultrasound equipment is generally more accessible than advanced CT or MRI infrastructure and can be used in decentralized diagnostic settings.
In Aug 2025, China approved Bracco's sulphur hexafluoride microbubbles for evaluating fallopian-tube patency through hysterosalpingo-contrast sonography.
Market Challenges
Operator Dependence and the Need for Standardized Procedures
Producing reliable CEUS results requires trained operators, correct contrast dosing, appropriate machine settings, and accurate interpretation of enhancement patterns. Image quality can be affected by patient movement, obesity, lesion depth, acoustic windows, and the timing of microbubble administration. Excessive acoustic power may destroy microbubbles before the required observations are completed. Differences among equipment platforms and clinical protocols can also make results difficult to compare across hospitals. Furthermore, healthcare facilities must maintain processes for intravenous access, patient observation, adverse-reaction management, and documentation. These requirements create workflow pressure and emphasize the need for standardized training, quality assurance, automated injection systems, and clearer clinical guidance across different applications.
In Aug 2026, Bracco's VueJect received U.S. FDA clearance and Health Canada authorization as a dedicated ultrasound contrast-delivery system designed to improve administration consistency in cardiac imaging.
Contrast Enhanced Ultrasound Market Segmentation Analysis
By Product
The equipment segment dominated the contrast enhanced ultrasound market with a market share of 61.8%, representing a value of USD 1.35 billion, and is projected to register a CAGR of 6.84%. Its leading position is supported by the growing installation of advanced ultrasound systems across hospitals, clinics, and diagnostic centers. Modern equipment offers contrast-specific imaging modes, improved transducers, low-mechanical-index capabilities, and real-time assessment of tissue perfusion. Demand is also increasing as healthcare facilities replace conventional systems with platforms that support cardiac, abdominal, vascular, and interventional imaging. Integration of artificial intelligence and automated workflows further improves diagnostic confidence and examination efficiency.
The contrast agent segment includes gas-filled microbubbles administered to improve the visibility of blood flow, cardiac chambers, and tissue vascularity during ultrasound examinations. Demand for these agents is increasing as contrast-enhanced ultrasound expands into liver lesion assessment, echocardiography, oncology, pediatrics, and inflammatory disease evaluation. New regulatory indications and the development of targeted microbubbles could broaden their clinical role further. Because contrast agents are consumed during individual procedures, their demand rises with examination volumes. Nevertheless, adoption depends on product availability, regulatory approval, reimbursement, clinician awareness, and the presence of trained personnel capable of safely preparing and administering the agents.
Request Customization to receive a tailored report.
By Type
The targeted segment is the fastest-growing category, accounting for a 27.4% market share and a value of USD 0.6 billion while recording a CAGR of 8.31%. Targeted microbubbles are designed to attach to specific biological markers associated with inflammation, abnormal blood vessel formation, and disease activity. This capability creates potential applications in molecular imaging, cancer evaluation, treatment monitoring, and inflammatory bowel disease. Growth is supported by continuing clinical research and increasing interest in diagnostic methods that combine real-time imaging with disease-specific information. Although the segment remains at an emerging stage, successful clinical trials and additional regulatory approvals could considerably expand its commercial adoption.
The non-targeted segment remains widely used because currently available agents can improve visualization without binding to a specific molecular marker. These microbubbles circulate through the bloodstream and help clinicians assess cardiac chambers, tissue perfusion, vascular patterns, and the characteristics of focal lesions. Their established role in echocardiography and liver imaging supports routine use in hospitals and diagnostic departments. The segment also benefits from recognized clinical protocols and greater physician familiarity. Future demand will be influenced by broader adoption in pediatric, renal, gastrointestinal, and interventional imaging, along with improvements in agent stability, ultrasound sensitivity, dosing practices, and standardized interpretation guidelines.
By End-Use
The hospitals segment led the contrast enhanced ultrasound market with a 56.7% share, equivalent to USD 1.24 billion, and is expected to expand at a CAGR of 7.02%. Hospitals perform large volumes of cardiac, liver, abdominal, emergency, and oncology examinations, creating strong demand for contrast-capable ultrasound equipment and microbubble agents. Their access to radiologists, cardiologists, sonographers, emergency physicians, and intravenous administration facilities supports more complex procedures. Hospitals also have greater resources to purchase advanced systems, train personnel, and implement safety protocols. Increasing patient admissions and the need for radiation-free bedside imaging are reinforcing the segment's leading market position.
Clinics serve patients requiring scheduled cardiac, abdominal, vascular, or follow-up examinations and benefit from the portability and comparatively accessible operating requirements of ultrasound technology. Adoption in this segment is improving as compact systems gain advanced contrast-imaging capabilities. Ambulatory diagnostic centers are also becoming important providers by offering convenient outpatient examinations, shorter waiting periods, and specialized imaging services. Their growth is supported by the shift toward decentralized care and efforts to reduce hospital workloads. However, adoption across both settings depends on referral volumes, reimbursement availability, equipment affordability, access to contrast agents, emergency preparedness, and the availability of operators trained in contrast administration and image interpretation.
Speak to an Analyst to discuss market opportunities.
Contrast Enhanced Ultrasound Market Regional Outlook
North America Contrast Enhanced Ultrasound Market Analysis
North America dominated the contrast enhanced ultrasound market with a market share of 39.5% and a value of USD 0.87 billion. The regional market is projected to register a CAGR of 7.05%. Its leading position is supported by the widespread availability of advanced diagnostic imaging systems, established healthcare facilities, and strong clinical acceptance of ultrasound-based examinations. Contrast-enhanced ultrasound is increasingly used for cardiac imaging, liver lesion characterization, blood-flow assessment, and other diagnostic applications. The presence of major equipment and contrast-agent companies also supports product availability, professional education, technology development, and the introduction of improved imaging workflows across the region.
United States Contrast Enhanced Ultrasound Market Insights
The United States represents an important market due to its advanced hospital infrastructure and strong adoption of innovative medical imaging technologies. Contrast-enhanced ultrasound is used across radiology, cardiology, emergency medicine, oncology, and pediatric care to improve the visualization of blood flow and tissue perfusion. Regulatory approvals covering multiple clinical applications encourage hospitals and imaging centers to incorporate the technique into diagnostic workflows. The presence of leading equipment manufacturers, pharmaceutical imaging companies, academic medical centers, and professional organizations supports research and physician education. Improving reimbursement conditions and continued development of automated contrast delivery systems are also expected to strengthen clinical utilization.
Canada Contrast Enhanced Ultrasound Market Insights
Canada offers favorable growth potential as healthcare providers increasingly seek diagnostic methods that deliver real-time imaging without ionizing radiation. Contrast-enhanced ultrasound is particularly relevant for evaluating liver abnormalities, cardiac structures, vascular patterns, and tissue perfusion. Major hospitals and academic healthcare institutions support its adoption through clinical research, specialist training, and multidisciplinary care programs. The technique can also help reduce dependence on more resource-intensive imaging procedures when clinically appropriate. Wider access will depend on consistent provincial reimbursement, availability of approved contrast agents, compatible ultrasound platforms, and adequately trained sonographers and physicians. Continued professional education could encourage more standardized use across Canadian healthcare facilities.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Contrast Enhanced Ultrasound Market Analysis
Europe was the fastest-growing region in the contrast enhanced ultrasound market, with a market share of 28.4% and a value of USD 0.62 billion. The region is anticipated to expand at a CAGR of 8.12%. Growth is supported by established clinical guidelines, increasing use of microbubble agents, and strong acceptance of ultrasound for liver, cardiac, gastrointestinal, and interventional imaging. European medical societies actively promote training and standardized clinical practices, helping healthcare professionals apply the technology across different specialties. Expanding pediatric applications, ongoing research into non-hepatic uses, and the presence of established ultrasound equipment and contrast-agent manufacturers are further strengthening regional development.
Germany Contrast Enhanced Ultrasound Market Insights
Germany is a prominent European market because of its well-developed healthcare system, strong diagnostic imaging capabilities, and extensive network of hospitals and specialist practices. Physicians use contrast-enhanced ultrasound for liver lesion characterization, abdominal imaging, vascular assessment, and selected interventional procedures. The country also benefits from active professional societies that support clinical education, technical standards, and evidence-based ultrasound practice. Domestic expertise in medical technology and a strong culture of specialist-led diagnostics encourage the adoption of advanced imaging tools. Further expansion will be supported by greater standardization, broader physician awareness, improved integration into clinical pathways, and continued training in contrast administration and image interpretation.
United Kingdom Contrast Enhanced Ultrasound Market Insights
The United Kingdom is experiencing growing interest in contrast-enhanced ultrasound as healthcare providers look for efficient diagnostic methods that can reduce unnecessary exposure to radiation. The technology is useful in liver imaging, cardiac assessment, lesion characterization, and the monitoring of tissue perfusion. Large hospitals and specialist imaging departments are well positioned to expand its use, while professional ultrasound organizations contribute to education and safe-practice guidance. Adoption may also help improve patient pathways when conventional ultrasound findings are unclear. Future development depends on consistent commissioning, access to suitable equipment and agents, greater awareness among referring clinicians, and expanded training for radiologists, sonographers, and other qualified practitioners.
Asia Pacific Contrast Enhanced Ultrasound Market Analysis
Asia Pacific accounted for 22.6% of the contrast enhanced ultrasound market and generated a value of USD 0.49 billion. The regional market is expected to record a CAGR of 7.68%. Demand is supported by expanding hospital infrastructure, growing diagnostic imaging volumes, and increasing awareness of radiation-free examination methods. Contrast-enhanced ultrasound is gaining relevance in liver imaging, cardiology, oncology, fertility assessment, and other specialist applications. The presence of major ultrasound equipment manufacturers and continued investment in medical technology support regional availability. Growth opportunities remain strong as healthcare providers modernize diagnostic departments, improve access to trained professionals, and adopt more advanced ultrasound and microbubble-based imaging protocols.
Japan Contrast Enhanced Ultrasound Market Insights
Japan has a mature medical imaging environment and a strong domestic base of ultrasound technology manufacturers. The country's healthcare providers use advanced ultrasound methods for liver disease assessment, oncology, cardiology, abdominal examinations, and treatment monitoring. An aging population and the need for repeatable diagnostic procedures support interest in contrast-enhanced ultrasound because it can provide real-time information without ionizing radiation. Japanese hospitals and research institutions also contribute to clinical evaluation, equipment development, and improvements in image-processing methods. Continued adoption will be encouraged by physician training, stronger integration with clinical guidelines, access to approved agents, and innovations that simplify examinations and improve diagnostic consistency.
China Contrast Enhanced Ultrasound Market Insights
China represents an important growth market due to the rapid modernization of hospitals, expanding diagnostic capacity, and increasing demand for advanced ultrasound examinations. Contrast-enhanced ultrasound is used for evaluating liver lesions, tissue blood flow, cardiac conditions, and several other clinical applications. Its potential role in fertility assessment also creates opportunities within women's healthcare and reproductive medicine. Local and international manufacturers are expanding the availability of ultrasound platforms with dedicated contrast-imaging functions. Broader market development will depend on regulatory approvals, clinician education, access to microbubble agents, and adoption beyond major urban hospitals. Improved standardization could further support its use in regional medical centers and specialist clinics.
Latin America Contrast Enhanced Ultrasound Market Analysis
Latin America held a 5.7% share of the contrast enhanced ultrasound market, corresponding to a value of USD 0.12 billion. The region is projected to grow at a CAGR of 6.41%. Market development is supported by gradual improvements in healthcare infrastructure, rising demand for noninvasive diagnostic imaging, and the installation of modern ultrasound equipment in hospitals and diagnostic centers. Contrast-enhanced ultrasound offers potential value where access to advanced imaging facilities is limited because ultrasound systems can support flexible clinical workflows. However, adoption varies across the region and depends on equipment availability, specialist training, reimbursement, contrast-agent approvals, and awareness among physicians responsible for diagnostic referrals.
Brazil Contrast Enhanced Ultrasound Market Insights
Brazil is a key Latin American market because of its large healthcare network, growing private diagnostic sector, and expanding use of ultrasound across medical specialties. Contrast-enhanced ultrasound can support liver imaging, cardiac examinations, oncology assessment, and vascular evaluation while avoiding ionizing radiation. Major hospitals and academic institutions are likely to remain the principal adopters because they have access to specialist physicians, suitable equipment, and intravenous administration capabilities. Opportunities also exist within outpatient diagnostic centers seeking to broaden their imaging services. Future growth will depend on regulatory access to contrast agents, reimbursement conditions, professional training, and greater awareness of appropriate clinical applications among referring doctors.
Middle East and Africa Contrast Enhanced Ultrasound Market Analysis
The Middle East and Africa represented 3.8% of the contrast enhanced ultrasound market, with a value of USD 0.08 billion and a CAGR of 5.92%. Regional demand is developing as governments and private healthcare groups invest in hospitals, specialist diagnostic centers, and advanced imaging equipment. Contrast-enhanced ultrasound can improve the evaluation of blood flow, cardiac structures, and focal lesions while providing a radiation-free imaging option. Market adoption remains concentrated in better-equipped healthcare facilities because the procedure requires compatible systems, approved agents, and trained operators. Wider expansion will depend on healthcare investment, regulatory availability, clinical education, and stronger distribution networks for equipment and consumable contrast products.
United Arab Emirates Contrast Enhanced Ultrasound Market Insights
The United Arab Emirates provides a favorable environment for contrast-enhanced ultrasound because of its modern hospitals, expanding private healthcare sector, and focus on advanced diagnostic services. Healthcare providers are increasingly interested in technologies that improve clinical accuracy while supporting efficient and patient-friendly examinations. Contrast-enhanced ultrasound can be applied in cardiology, liver imaging, oncology, abdominal assessment, and selected emergency cases. The country's medical tourism strategy may also encourage leading hospitals to adopt specialized imaging capabilities. Further growth will rely on the availability of approved microbubble agents, training for radiologists and sonographers, integration into hospital protocols, and collaboration between healthcare providers and international medical technology companies.
Contrast Enhanced Ultrasound Market Competitive Landscape
Competition involves ultrasound-system manufacturers, microbubble-agent producers, software developers, and specialized imaging companies. GE HealthCare, Siemens Healthineers, Canon Medical, Philips, Samsung Medison, Mindray, Esaote, Bracco, and Lantheus compete through image quality, workflow automation, approved indications, clinical evidence, and hospital partnerships. Equipment suppliers are improving contrast-specific modes, transducers, and artificial intelligence, while pharmaceutical companies are expanding microbubble applications and developing targeted agents. Regulatory approvals provide an important advantage because indications differ across countries and patient groups. Partnerships between equipment and contrast-agent companies are also increasing, as coordinated development can improve dosing, image acquisition, interpretation, and clinical training while accelerating CEUS adoption across additional medical specialties.
List of Key and Emerging Players in Contrast Enhanced Ultrasound Market
G.E. Healthcare
Siemens Healthineers AG
Esaote SPA
Lantheus Medical Imaging, Inc
Bracco Diagnostics Inc
Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
NanoPET Pharma GmbH
Key Industry Developments
March 2026: Bracco Imaging and Canon Medical Systems Europe announced a strategic collaboration at ECR 2026 by co-hosting a scientific symposium focused on advancing Contrast-Enhanced Ultrasound (CEUS), highlighting innovations to improve diagnostic efficiency, radiology workflows, and clinical adoption.
November 2025: Canon Medical Systems received U.S. FDA 510(k) clearance for Version 9.0 of its Aplio i-series ultrasound systems, introducing advanced imaging technologies that enhance image quality and workflow efficiency for ultrasound applications, including CEUS.
September 2025: Philips, GE HealthCare, and Samsung Medison showcased advanced Contrast-Enhanced Ultrasound technologies at the Korean Congress of Radiology, highlighting microvascular imaging and improved lesion characterization.
Report Scope
Comments
No comment